奥沙利铂联合卡培他滨治疗晚期胃癌的研究

目的 评价奥沙利铂联合卡培他滨方案治疗进展及转移胃癌的疗效与安全性。方法奥沙利铂130mg／m^2．静脉滴注2h，第1d；卡培他滨2500mg／m^2，分早晚2次口服，第1～14d，每3周重复，行2周期治疗后判定疗效。结果入组观察40例，其中行原发灶切除者14例，未切除者26例。可评价疗效者40例，其中完全有效（CR）4例（10．0％），部分有效（PR）20例（50．0％），稳定（SO）8例（20．0％），进展（PD）8例（20．0％）。有效率（ORR）60．0％（24／40），初治（一线）ORR 66．7％（20／30），复治（二线以上）ORR 40．0％（4／10）。中位无进展期（mTTP）9．7个月，中位总生存期（mOS）13．5个月。毒副作用手足综合征、神经毒性，多为Ⅰ～Ⅱ度。结论奥沙利铂联合卡培他滨方案治疗晚期胃癌疗效高，毒副作用小，患者易耐受，生活质量提高。

Combination of oxaliplatin and capecitabine in the treatment of advanced/metastatic gastric cancer

Objective To evaluate the effects and safety of combination of oxaliplatin and capecitabine （XELOX） regimen for patients with advanced/metastatic gastric cancer. Methods Oxaliplatin 130 mg/m^2 iv 24r dl, capccitabine 2 500 mg/m^2 , twice a day for two weeks, Every 3 weeks was a cycle. Efficacy was evaluated after 2 cycles. Results Forty patients have been entered into the study. Patients with or without primary tumor resected were 14 and 26 respectively. Forty patients were evaluable for clinical response. Four patients achieved complete response （ CR, 10.0% ）, 20 patients partial response （ PR, 50.0% ）. The overall response rate （ORR） was 60.0% （24/40）. Eight patients showed stable dis- ease （SD, 20.0% ） and 8 patients showed progressive disease （PD, 20.0% ）. ORR for chemotherapy- naive （Ist. line） and prctreated （2nd. line） patients were 66.7% （20/30） and 40.0% （4/10）, respectively. Median time to progress （mTFP） was 9.7 months and median overall survival （mOS） was 13.5 months. The major side effects were hand - foot syndrome. Conclusion XELOX is a high response regimen for advanced gastric cancer with mild toxicity, which can be practiced safely